Compare NDMO & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NDMO | IMNM |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 601.2M | 2.5B |
| IPO Year | 2019 | 2020 |
| Metric | NDMO | IMNM |
|---|---|---|
| Price | $8.81 | $21.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $32.80 |
| AVG Volume (30 Days) | 281.4K | ★ 975.9K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,941,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,127.34 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.77 | $11.09 |
| 52 Week High | $10.82 | $30.06 |
| Indicator | NDMO | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 19.61 | 31.21 |
| Support Level | N/A | $19.39 |
| Resistance Level | $10.47 | $23.25 |
| Average True Range (ATR) | 0.18 | 1.19 |
| MACD | -0.04 | -0.42 |
| Stochastic Oscillator | 7.19 | 1.42 |
Nuveen Dynamic Municipal Opportunities is a closed-end management investment company. Its investment objective is to seek total return through income exempt from regular federal income taxes and capital appreciation. A majority of its investments are made in municipal securities, the income from which is exempted from regular federal income taxes.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.